Johnson Johnsons dual-targeting CAR T-cell therapy shows encouraging . . . Johnson Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19 CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R R LBCL) who have not been previously treated with CAR T-cell therapy
Johnson Johnson’s dual-targeting CAR T-cell therapy shows encouraging . . . MILAN (June 13, 2025) – Johnson Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19 CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R R LBCL) who have not been previously
Our leadership team - Johnson Johnson Joseph J Wolk (Joe) is the Executive Vice President and Chief Financial Officer for Johnson Johnson Joe serves as a member of the company’s Executive Committee, playing a strategic role in the overall management of the organization and leading the development and execution of the business’ global long-term financial strategy
Johnson Johnson showcases latest advancements in cancer innovation . . . †See the NCCN Guidelines for detailed recommendations, including other treatment options ‡ The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays or commercial laboratories § The NCCN Content does not constitute medical advice
Johnson Johnson WARNING NOTICE: This system is restricted solely to Johnson Johnson users for legitimate business only The actual or attempted unauthorized access, use or modification of this system is strictly prohibited by Johnson Johnson Unauthorized users are subject to Company disciplinary proceedings and or criminal and civil penalties under state, federal or other applicable domestic and foreign
Locations | Johnson Johnson Careers Learn about the regions and countries where J J operates and explore career opportunities, search for jobs and apply to join us wherever you are in the world
portman. jnj. com WARNING NOTICE: This system is restricted solely to Johnson Johnson users for legitimate business only The actual or attempted unauthorized access, use or modification of this system is strictly prohibited by Johnson Johnson Unauthorized users are subject to Company disciplinary proceedings and or criminal and civil penalties under state, federal or other applicable domestic and foreign
Johnson Johnson: Changing health for humanity Johnson Johnson MedTech innovates at the intersection of biology and technology With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex diseases
Johnson Johnson Note: Your browser does not support JavaScript, Press Continue to proceed